HUTCHMED (China) (HMDCF) Cash from Financing Activities (2018 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Cash from Financing Activities came in at $605.1 million in Q2 2021, up 4315.1% year-over-year from $13.7 million in Q2 2020, and up 2362.23% quarter-over-quarter from -$26.7 million in Q1 2021.
Analysis
HUTCHMED (China) (HMDCF) Cash from Financing Activities (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Cash from Financing Activities for 4 consecutive years, with $605.1 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Cash from Financing Activities rose 4315.1% year-over-year to $605.1 million in Q2 2021; TTM through Jun 2021 was $674.7 million, a 442.5% increase from a year earlier, with the FY2025 full-year figure at $7.8 million, up 125.55% from the prior year.
- Cash from Financing Activities was $605.1 million for Q2 2021 at HUTCHMED (China), up from -$26.7 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $605.1 million in Q2 2021 and troughed at -$29.2 million in Q2 2019.
- A 4-year average of $56.8 million and a median of -$161000.0 in 2018 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities tumbled 1017.16% in 2019 and soared 32093.64% in 2020, its largest moves.
- Over 4 years, Cash from Financing Activities stood at $16.0 million in 2018, then surged by 67.63% to $26.9 million in 2019, then tumbled by 153.36% to -$14.4 million in 2020, then surged by 4315.1% to $605.1 million in 2021.
- The last three Cash from Financing Activities figures came in at $605.1 million (Q2 2021), -$26.7 million (Q1 2021), and -$14.4 million (Q2 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -181.51 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 605.08 Mn |
| Mar 31, 2021 | -26.75 Mn |
| Jun 30, 2020 | -14.36 Mn |
| Mar 31, 2020 | 110.70 Mn |
| Dec 31, 2019 | 26.90 Mn |
| Sep 30, 2019 | 1.12 Mn |
| Jun 30, 2019 | -29.17 Mn |
| Mar 31, 2019 | -346,000.00 |
| Dec 31, 2018 | 16.05 Mn |
| Sep 30, 2018 | 24,000.00 |
| Jun 30, 2018 | -2.61 Mn |
| Mar 31, 2018 | -5.23 Mn |